Journal: Science Advances
Article Title: A beneficial environment promotes immune resilience through epigenetic regulation
doi: 10.1126/sciadv.ady7317
Figure Lengend Snippet: ( A ) Volcano plot showing DEGs in OVA versus OVA + FD MDMs, analyzed by model-based analysis of single-cell transcriptomics (MAST). ( B ) Ccl8 gene expression in OVA versus OVA + FD. ( C ) Mouse serum CCL8 measured by enzyme-linked immunosorbent assay. ( D ) Serum CCL8 levels in human patients with asthma versus healthy controls. ( E ) WT mice were sensitized to OVA and treated daily with anti-CCL8 antibody or isotype 6 hours before OVA challenge. Representative BAL Giemsa cytospins and PAS-stained lung sections are shown. ( F ) Quantification of BAL eosinophils and ( G ) volume of mucus. ( H ) Lung inflammatory eosinophils (CD45 + , Ly6g neg , CD125 int , SiglecF +, CD11c + , and CD101 + ) quantified by flow cytometry. ( I and J ) CCL8 gene expression in murine BMDMs and human monocytes after 48 hours of FD exposure followed by 6 hours of LPS stimulation. ( K ) Average gene expression from MHCII-related genes ( H2-Eb1 , H2-Ab1 , H2-Aa , and Ciita ) were down-regulated in OVA + FD MDMs. ( L ) MHCII mean fluorescence intensity (MFI) on lung MDMs (CD45 + , F4/80 + , Ly6G neg , CD11b + , and CCR2 + ). ( M ) HLA-DR MFI in human monocyte–derived APCs exposed to FD for 48 hours and LPS for 6 hours. ( N ) BMDMs pulsed with OVA 323–339 peptide after FD and LPS stimulation and then cocultured with naive CD4 + T cells. T cell proliferation assessed by CellTrace™ Violet (CTV) MFI-based division index. ( O ) Proliferation-associated gene ( Cenpe , Top2a , and Mki67 ) average expression within CD4 + T cell subset in OVA versus OVA + FD. Modules were clustered by KEGG/Reactome terms; antigen presentation node shows altered interaction strength. Results are plotted as means ± SEM, and difference between means were compared using one-way ANOVA followed by Tukey’s post hoc test ( n = 4 to 19).
Article Snippet: Mouse CCL8 (BioLegend, no. 446904), human CCL8 (BioLegend, no. 442204), OVA-specific IgE (Chondrex, no. 3004), and OVA-specific IgG1 (Chondrex, no. 3013) were used according to the supplier’s protocols.
Techniques: Single-cell Transcriptomics, Gene Expression, Enzyme-linked Immunosorbent Assay, Staining, Flow Cytometry, Fluorescence, Derivative Assay, Expressing, Immunopeptidomics